Feb 17, 2026 09:27AM
Jan 23, 2026 08:00AM
Dec 16, 2025 07:00AM
Dec 16, 2025 07:00AM
Oct 31, 2025 07:00AM
Oct 31, 2025 07:00AM
Sep 3, 2025 09:05AM Adagene names Axel Hoos as executive advisor
Sep 3, 2025 09:05AM
Aug 15, 2025 06:53AM
Aug 12, 2025 04:05PM
Jul 15, 2025 07:01AM
Jul 15, 2025 07:00AM
Mar 24, 2025 08:00AM
Sep 16, 2024 03:01AM Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metas
Feb 9, 2024 06:01AM
Feb 9, 2024 06:00AM
Jan 9, 2023 07:02AM
Jan 9, 2023 07:00AM
Jan 9, 2023 07:00AM
Dec 16, 2022 06:32AM
Dec 16, 2022 06:30AM Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer
Dec 16, 2022 06:30AM
Mar 31, 2022 08:30AM
Mar 31, 2022 08:30AM
Mar 16, 2022 07:00AM
Mar 16, 2022 07:00AM
Feb 2, 2022 04:23PM
Feb 2, 2022 04:05PM Adagene Announces Board and Management Appointments to Support Pipeline Growth
Nov 30, 2021 09:28AM
Nov 29, 2021 06:03PM
Nov 29, 2021 04:06PM
Nov 29, 2021 04:05PM
Aug 26, 2021 07:45AM
Aug 26, 2021 07:45AM
Aug 12, 2021 07:45AM Adagene Inc. (ADAG) Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory Board
Aug 12, 2021 07:45AM
Aug 12, 2021 07:45AM
May 19, 2021 05:10PM
May 19, 2021 05:05PM
May 19, 2021 05:05PM
May 6, 2021 04:05PM
Mar 31, 2021 07:45AM Adagene Reports Full Year 2020 Financial Results and Provides Corporate Updates
Mar 31, 2021 07:45AM
Mar 29, 2021 07:45AM
Mar 29, 2021 07:45AM
Mar 29, 2021 07:45AM
Mar 16, 2021 08:10AM
Mar 16, 2021 08:05AM
Mar 16, 2021 08:05AM Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ Program
Feb 10, 2021 04:05PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All